Advanced Filters
noise

Hormone Deficiencies Clinical Trials

A listing of Hormone Deficiencies medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Found 85 clinical trials
C Craig Ziering, MD

Autologous Hair Follicle Secretome for Androgenic Alopecia (Single Site)

(SINGLE SITE Study) The purpose of this clinical trial is to evaluate the safety and efficacy of the use of an autologous hair follicle derived secretome for androgenous alopecia. The secretome will be injected into the scalp at baseline, and days 30, 90, 180, 270 and 365. Hair growth will …

18 - 65 years of age All Phase N/A
H Hailey Konisky, BS

1470nm Laser for the Treatment of Androgenetic Alopecia and Scarring Alopecia

Single-center, open-label, baseline-controlled, pilot study evaluating the use of a Nonablative 1470 nm laser for the treatment of androgenetic alopecia and scarring alopecia.

18 - 99 years of age All Phase N/A

Study to Evaluate Safety & Usability of a New Formulation for Male Androgenetic Alopecia

The CSP-001-FOL1 clinical study is aimed to investigate whether local topical administration of FOL100 lotion will be safe for the patient and will not cause local or systemic skin or other adverse events. It is also aimed at indicating effectiveness as compared with oral Finasteride 1mg. In this non-blinded study, …

18 - 40 years of age Male Phase 1

Safety and Efficacy of VDPHL01 in Males With AGA

This study will evaluate the safety and efficacy of VDPHL01 in male subjects with Androgenetic Alopecia (AGA). AGA (or male pattern baldness) is a genetic disorder caused by an excessive (too much) hair follicle response to androgens (hormone) that causes hair loss. VDPHL01 8.5 mg Tablet is an investigational oral …

18 - 65 years of age Male Phase 3

Sham LaserCap vs. LaserCap SD vs. LaserCap HD+

Androgenetic alopecia (AGA) is a prevalent disease, occurring in 80% of Caucasian men and 50% of Caucasian women by age 701. Treatments for AGA are limited, and presently the only FDA-approved medications for AGA are topical minoxidil and oral finasteride1. In addition to medical therapies, FDA-cleared medical devices are now …

25 years of age All Phase N/A
L Laita Bokhari, MPhil Med

Efficacy & Safety of Minoxidil SL Tablets in Men With AGA

This is a phase 3, multicentre, randomised, double-blinded, placebo-controlled study examining the safety and efficacy of 2.5 mg sublingual (SL) minoxidil tablets taken twice daily in the treatment of androgenetic alopecia (AGA) in men. The duration of study participation is 32 weeks including screening and safety follow up. The primary …

18 years of age Male Phase 3
L Linyu Zhu

Efficacy and Safety of 5% Minoxidil Foam in Female Androgenetic Alopecia

The primary objective of this study is to evaluate the efficacy of once-daily 5% minoxidil foam versus placebo in female androgenetic alopecia, using the Target Area Terminal Hair Count (TAHC) as the primary endpoint.

18 years of age Female Phase 3
C Cheng Zhou

Clinical Trial to Evaluate CG2001 in Chinese Adult Male Participants With Androgenetic Alopecia

The main objectives of this study are to preliminarily evaluate the effectiveness of CG2001 in treating Chinese adult male AGA participants, determine the recommended dose for Phase III clinical studies, and evaluate the safety of CG2001 at the target dose.

18 - 65 years of age Male Phase 2
L L Nguyen

Thulium Laser and Growth Factors for Androgenetic Alopecia

Androgenetic alopecia (AGA) is a common cause of hair loss worldwide. It mainly affects the frontal and parietal regions of the scalp in up to 70 % of men and 40 % of women and has a significant negative psychological and emotional impact on those affected. Various therapies are currently …

18 years of age All Phase N/A
Z Zhenjun Deng, Ph.D

A Randomized Controlled Clinical Study on the Treatment of Androgenetic Alopecia in Young Men With Umbilical Cord Mesenchymal Stem Cell Exosomes

This clinical trial aims to determine the efficacy of human umbilical cord mesenchymal stem cell exosomes (hUCMSC-sEV) in treating androgenic alopecia in young men. It will also investigate the safety of hUCMSC-sEV. The primary inquiry it seeks to address is: Do hUCMSC-sEV demonstrate efficacy in the treatment of androgenic alopecia …

18 - 35 years of age Male Phase 1/2

Simplify language using AI